蘑菇视频APP

CAMBRIDGE, Mass., August 14, 2023 鈥� 蘑菇视频APP, the bioplatform innovation company, and Ampersand Biomedicines, a company programming smarter medicines that act specifically at the site of disease and nowhere else, today announced that Jason Gardner, Ph.D., has joined 蘑菇视频APP as CEO-Partner, and Ampersand as Chief Executive Officer and member of its Board of Directors.

Gardner brings more than two decades of leadership experience across pharmaceutical and biotechnology companies, with deep expertise in drug discovery and development, and a successful track record of securing strategic partnerships, scaling companies, and building teams.

Gardner was most recently the CEO, President, and Co-Founder of Magenta Therapeutics. At Magenta, he led the company as it advanced key programs into the clinic, completed a successful IPO, and scaled to more than 100 employees. Prior to this role, he held multiple positions of increasing responsibility at GSK, including serving as the head of Research & Development in Boston, creating and leading the company鈥檚 Regenerative Medicine Unit, and establishing partnerships with Harvard鈥檚 Stem Cell Institute and The Telethon Institute for Gene Therapy. In addition, Gardner was head of the Center of Excellence for External Drug Discovery at GSK, where he led a team that oversaw more than 42 programs across five therapeutic areas.

鈥淛ason brings extensive experience that spans the breadth of the biopharma industry, and his presence and leadership will greatly benefit Ampersand and Flagship鈥檚 ecosystem,鈥� said Noubar Afeyan, Ph.D., Founder and CEO of 蘑菇视频APP and Co-Founder and Chairman of Ampersand Biomedicines. 鈥淎s Ampersand focuses on its next stage of growth, Jason鈥檚 expertise in bringing novel therapeutics from concept to clinic will be crucial in driving Ampersand forward for the ultimate benefit of patients.鈥�

鈥淎mpersand is ushering in a drug development revolution to program medicines that effectively target the site of disease without affecting healthy tissue or cells,鈥� said Avak Kahvejian, Ph.D., 蘑菇视频APP General Partner and Co-Founder, Founding CEO and Board Director of Ampersand Biomedicines. 鈥淎mpersand will benefit immensely from Jason鈥檚 leadership, including his successful track record of scaling, partnering, and advancing novel therapeutics and bioplatforms across therapeutic areas, as the company works to realize the vast potential of its AND鈩� Platform.鈥�

鈥淐reating medicines that specifically and safely act on the diseased organ or tissue and nowhere else has long been one of the greatest challenges in drug development, but Ampersand has an opportunity to change this paradigm,鈥� said Jason Gardner, Ph.D., CEO and Board Director of Ampersand Biomedicines and 蘑菇视频APP CEO-Partner. 鈥淚 look forward to leading the company on its mission to program smarter medicines and create a new standard in biologics discovery and development.鈥�

About Ampersand Biomedicines

Ampersand Biomedicines enables a new way of programming smarter medicines that work precisely where needed in the body and nowhere else. The company鈥檚 versatile computationally powered Address, Navigate, Design (AND)鈩� Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body鈩� therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2021 at Flagship Labs, a unit of 蘑菇视频APP. For more information, please visit .

About 蘑菇视频APP

蘑菇视频APP conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in more than $90 billion in aggregate value. To date, Flagship has deployed over $3.4 billion in capital toward the founding and growth of its pioneering companies alongside more than $26 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 45 transformative companies, including Denali Therapeutics (NASDAQ:), Foghorn Therapeutics (NASDAQ:), Generate Biomedicines, Inari, Indigo Agriculture, Moderna (NASDAQ:), Omega Therapeutics (NASDAQ:), Sana Biotechnology (NASDAQ:), Seres Therapeutics (NASDAQ:) and Tessera Therapeutics.